Sort   by:  
 Page size 
UnknownPhase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Not available
S-EPMC3675699 | biostudies-literature
UnknownProlonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
Not available
S-EPMC3986386 | biostudies-literature
Transcriptomics5-azacytidine and entinostat treatment of patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. The patients with MDS, chronic myelomonocytic leukemia (CMMoL), and high risk AML were treated with sequential administration of ...
ORGANISM(S): Homo sapiens 
2009-06-20 | E-GEOD-16625 | biostudies-arrayexpress
Genomicsena-DATASET-CRUK-LRI-04-02-2014-11:46:00:265-3 - samples
Paired end Illumina sequencing of whole exomes of multiple tumour regions.
EGAD00001000734 | EGA
GenomicsGenomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing
We applied multi-region exome sequencing to 10 clear cell renal carcinomas to resolve the genetic architecture, intra tumour heterogeneity and evolutionary histories of these tumours.
EGAS00001000667 | EGA
GenomicsTRACERx renal DAC
Data Access Committee EGAC00001001907
EGAC00001001907 | EGA
Sort   by:  
 Page size